ストックスクリーナーアプリを入手
20.36
0.44%
0.09
アフターアワーズ：
20.36
前日終値:
$20.27
開ける：
$19.55
24時間の取引高:
2.38M
Relative Volume:
13.45
時価総額：
$680.38M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+7.50%
1か月 パフォーマンス:
+25.37%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$19.21
$21.64
1週間の範囲:
$17.93
$21.64
52週間の値動き範囲:
$15.31
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
MBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
20.36 | 680.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | JP Morgan | Overweight |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Stifel | Buy |
Mbx Biosciences Inc (MBX) 最新ニュース
MBX Biosciences (NYSE:MBX) Shares Gap DownShould You Sell? - MarketBeat
Teachers Retirement System of The State of Kentucky Makes New $694,000 Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
MBX Biosciences (NYSE:MBX) Trading 4.6% HigherHere's Why - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Gap UpWhat's Next? - MarketBeat
The Manufacturers Life Insurance Company Invests $1.20 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Wellington Management Group LLP Takes $74.26 Million Position in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Frazier Life Sciences Management L.P. Makes New $155.50 Million Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
Maven Securities LTD Makes New $1.30 Million Investment in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
RA Capital Management L.P. Takes $39.26 Million Position in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism - The Manila Times
MBX Biosciences Announces MBX 2109 Phase 1 Study Results - GlobeNewswire
NEA Management Company LLC Invests $93.90 Million in MBX Biosciences, Inc. (NYSE:MBX) - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Down 3.6% – Should You Sell? - Defense World
MBX Biosciences (NYSE:MBX) Shares Down 3.6%Time to Sell? - MarketBeat
MBX Biosciences (NYSE:MBX) Trading Up 6.5%Still a Buy? - MarketBeat
MBX Biosciences completes phase 1 trial of diabetes drug By Investing.com - Investing.com Canada
MBX Biosciences completes phase 1 trial of diabetes drug - Investing.com India
MBX Biosciences Announces Last Subject Last Visit in Phase - GlobeNewswire
Mbx Biosciences, Inc. Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia - Marketscreener.com
MBX Biosciences (NYSE:MBX) Reaches New 12-Month Low – Here’s Why - Defense World
MBX Biosciences (NYSE:MBX) Sets New 1-Year LowTime to Sell? - MarketBeat
MBX Biosciences: Decent Potential For Lead Indication, But Need More Data (NASDAQ:MBX) - Seeking Alpha
Behind the Bell: MBX Biosciences - Nasdaq
MBX Biosciences Reports Q3 2024 Financial Progress - MSN
Wellington Management Group LLP Acquires New Stake in MBX Biosci - GuruFocus.com
MBX Biosciences Inc. (MBX) Quarterly 10-Q Report - Quartzy
MBX Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
MBX Biosciences Secures $251M in IPO, Advances Clinical Pipeline with Strong Cash Position | MBX Stock News - StockTitan
MBX Biosciences (NYSE:MBX) Shares Up 8.2%Time to Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Up 6.8%Should You Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Sets New 52-Week LowTime to Sell? - MarketBeat
MBX Biosciences to Participate in Upcoming November Investor Conferences - The Manila Times
MBX Biosciences (NYSE:MBX) Shares Down 4.5%Here's What Happened - MarketBeat
MBX Biosciences sets IPO terms with plans to raise up to $136 million - MSN
MBX Biosciences, Inc.'s (NYSE:MBX) Quiet Period To End on October 23rd - MarketBeat
MBX Biosciences, Inc.’s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Stock Price Down 4%Here's Why - MarketBeat
MBX Bio drops despite bullish views on Street - MSN
Mbx Biosciences Inc (MBX) 財務データ
Mbx Biosciences Inc (MBX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):